Zydus Therapeutics reports positive phase-3 results in rare liver disease
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
Subscribe To Our Newsletter & Stay Updated